Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
US10072086B2 · kind B2 · utility
9Cited by
20References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2015 |
| Grant date | Sep 11, 2018 |
| Priority date | — |
| Expiry date | Jun 3, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.